India Achieves Milestone in Gene Therapy for Haemophilia
| Category | Details |
|---|---|
| Event | India's first-in-human gene therapy trial for Haemophilia |
| Institutions Involved | BRIC-inStem, CMC Vellore |
| Key Figure | Dr. Jitendra Singh, Union Minister |
| Sector Growth | Biotech sector grew 16-fold in a decade, reaching $165.7 billion in 2024; aims for $300 billion by 2030. |
| Policy Driving Growth | BIO-E3 Policy (Economy, Employment, Environment) |
| Startups | Over 10,000 biotech startups, up from 50 ten years ago. |
| Innovations by BRIC | Germicidal anti-viral mask (COVID-19 era), Kisan Kavach (protects farmers from neurotoxic pesticides) |
| Institutional Reforms | Formation of Biotechnology Research and Innovation Council (BRIC); unified 14 autonomous research bodies under one umbrella. |
| Infrastructure | Biosafety Level III Laboratory (key for One Health Mission and pandemic preparedness), CReATE Centre (focuses on embryology, infertility, and birth defect research). |
| Future Directions | Initiate MD-PhD programs, improve communication outreach, enhance national-level visibility of BRIC-inStem's work. |
| Significant Milestones | Gene therapy trial marks a milestone; biotech sector recognized as a strategic pillar for India's future economic growth and healthcare advancement. |